BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Melanoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Melanoma\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06712927-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, N
 ivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic Me
 lanoma Brain Metastases\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712927-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, 
 Nivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic M
 elanoma Brain Metastases\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712927-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, 
 Nivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic M
 elanoma Brain Metastases\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04283890-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04283890)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: PHP and Immunotherapy
  in Metastasized UM\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04283890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04283890-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT04283890)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: PHP and Immunotherap
 y in Metastasized UM\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04283890
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03915678-1962@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03915678)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03915678
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02644369-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02644369)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of the 
 Effects of Pembrolizumab in Patients With Advanced Solid Tumors\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02644369
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340129-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03340129)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Anti-PD 1 Brain Collabo
 ration + Radiotherapy Extension (ABC-X Study)\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03340129
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340129-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03340129)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Anti-PD 1 Brain Collab
 oration + Radiotherapy Extension (ABC-X Study)\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03340129
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669430-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembro
 lizumab in Participants With Solid Tumor Malignancies\nEstimated primary c
 ompletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05669430
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05315258-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT05315258)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Melanoma.\nStudy: Teben
 tafusp in Molecular Relapsed Disease (MRD) Melanoma\nEstimated primary com
 pletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tebentafusp-tebn#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05315258
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03685890-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03685890)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Evaluating the Effect
  of Nivolumab for Patients With In-transit Metastases Treated With Isolate
 d Limb Perfusion\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03685890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04708418-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04708418)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: A Study Evaluating 
 Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Effica
 cy of Treatment in Patients With Operable Melanoma\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04708418
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155317-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07155317)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Time-of-Day Specified I
 mmunotherapy for Advanced Melanoma\, The TIME Trial\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07155317
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155317-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07155317)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Time-of-Day Specified 
 Immunotherapy for Advanced Melanoma\, The TIME Trial\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07155317
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03313206-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03313206)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Treatme
 nt Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patien
 ts With Resectable Head and Neck Mucosal Melanoma\nEstimated primary compl
 etion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03313206
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06237881-5442@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT06237881)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: A Phase
  1/2 Study of KSQ-001EX\, Autologous Tumor Infiltrating Lymphocytes Engine
 ered to Inactivate the SOCS1 Gene\, in Patients With Select Advanced Solid
  Tumors\nEstimated primary completion: 1 January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06237881
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136196-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05136196)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivo
 lumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and 
 Neck Cancer\, an immunoMATCH Pilot Study\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5136196
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the 
 Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab f
 or Preventing or Delaying Melanoma From Coming Back After it Has Been Remo
 ved With Surgery\nEstimated primary completion: 15 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Fianlimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the C
 ombination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab fo
 r Preventing or Delaying Melanoma From Coming Back After it Has Been Remov
 ed With Surgery\nEstimated primary completion: 15 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250335-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06250335)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Impact of a Prebiotic F
 ood-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combin
 ation Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
 \nEstimated primary completion: 23 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06250335
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250335-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06250335)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Impact of a Prebiotic 
 Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combi
 nation Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patient
 s\nEstimated primary completion: 23 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06250335
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Binimetinib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Binimetinib\, phase 1/2\, Melanoma.\nStudy: Study of IDE196 in 
 Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions\nEs
 timated primary completion: 29 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376317-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07376317)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Optimization of Imm
 unotherapy Treatment for Advanced Melanoma in the Context of the Public Br
 azilian Health System (OTIMAS)\nEstimated primary completion: 30 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073763
 17
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ i
 n Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pemb
 rolizumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ in Me
 lanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembroli
 zumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ in M
 elanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrol
 izumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462406-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04462406)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Using Biomarkers to He
 lp Guide Safe Immunotherapy Discontinuation in Patients With Unresectable 
 Stage IIIB-IV Melanoma\, The PET-Stop Trial\nEstimated primary completion:
  31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipi
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04462406
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417621-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Trametinib: Phase 2 readout est. (NCT04417621)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Study of Efficacy and 
 Safety of LXH254 Combinations in Patients With Previously Treated Unresect
 able or Metastatic Melanoma\nEstimated primary completion: 2 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04417621
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026983-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Binimetinib: Phase 2 readout est. (NCT05026983)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Binimetinib and Encor
 afenib for the Treatment of Metastatic Melanoma and Central Nervous System
  Metastases\nEstimated primary completion: 2 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05026983
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026983-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05026983)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Binimetinib and Encor
 afenib for the Treatment of Metastatic Melanoma and Central Nervous System
  Metastases\nEstimated primary completion: 2 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05026983
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319196-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06319196)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Clear Me: Interception 
 Trial to Detect and Clear Molecular Residual Disease in Patients With High
 -risk Melanoma\nEstimated primary completion: 15 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06319196
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R
 α Binding\, in Patients With Unresectable Locally Advanced or Metastatic 
 Cancer\nEstimated primary completion: 28 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-5442@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Study o
 f AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα B
 inding\, in Patients With Unresectable Locally Advanced or Metastatic Canc
 er\nEstimated primary completion: 28 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289193-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05289193)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: CD8+ T Cell Imaging Dur
 ing Pre-surgery Immunotherapy in People With Melanoma\nEstimated primary c
 ompletion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05289193
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289193-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05289193)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: CD8+ T Cell Imaging Du
 ring Pre-surgery Immunotherapy in People With Melanoma\nEstimated primary 
 completion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05289193
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02196181-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Trametinib: Phase 2 readout est. (NCT02196181)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Testing Two Different 
 Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has
  Spread\nEstimated primary completion: 15 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02196181
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02196181-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02196181)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Testing Two Different 
 Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has
  Spread\nEstimated primary completion: 15 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02196181
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Study With Combinati
 ons of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva
 nced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary comp
 letion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06246916
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Fianlimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Study With Combinatio
 ns of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advan
 ced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary compl
 etion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06246916
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Encorafenib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Encorafenib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122522-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03122522)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study to Evaluate Ada
 ptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03122522
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122522-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03122522)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study to Evaluate Ad
 aptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy\nEstim
 ated primary completion: April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03122522
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221734-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07221734)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Study to Compare Pharma
 cokinetics\, Efficacy\, Safety\, and Immunogenicity of MB11 Versus EU-/US-
 Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or M
 etastatic] Melanoma\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07221734
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02231775-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Trametinib: Phase 2 readout est. (NCT02231775)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Dabrafenib and Trameti
 nib Before and After Surgery in Treating Patients With Stage IIIB-C Melano
 ma With BRAF V600 Mutation\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02231775
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02231775-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02231775)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Dabrafenib and Trameti
 nib Before and After Surgery in Treating Patients With Stage IIIB-C Melano
 ma With BRAF V600 Mutation\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02231775
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04971499-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04971499)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Melanoma.\nStudy: A Study of Dapans
 utrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melano
 ma\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04971499
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384496-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05384496)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Axitinib and Nivolumab 
 for the Treatment of Mucosal Melanoma\nEstimated primary completion: May 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05384496
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384496-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05384496)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Axitinib and Nivolumab
  for the Treatment of Mucosal Melanoma\nEstimated primary completion: May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05384496
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04598009-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04598009)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Binimetinib and Imati
 nib for Unresectable Stage III-IV KIT-Mutant Melanoma\nEstimated primary c
 ompletion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04598009
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastat
 ic Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Dabrafenib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906822-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06906822)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: PLUG-IN: Pembrolizu
 mab Combined With Enfortumab Vedotin for Advanced Melanoma Patients\nEstim
 ated primary completion: June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06906822
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912244-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05912244)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study of IO102/IO103\
 , Nivolumab\, and Relatlimab in People With Melanoma\nEstimated primary co
 mpletion: 9 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05912244
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912244-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05912244)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: A Study of IO102/IO103
 \, Nivolumab\, and Relatlimab in People With Melanoma\nEstimated primary c
 ompletion: 9 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05912244
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Thera
 py + Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05034536
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Therapy +
  Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05034536
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Therapy 
 + Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050345
 36
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study to Compare the 
 Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab 
 + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: A Study to Compare th
 e Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimuma
 b + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study to Compare the
  Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab
  + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Encorafenib: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: A Study to Compare th
 e Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimuma
 b + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829254-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03829254)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Safety\, Ph
 armacokinetic and Clinical Activity Study of NUC-7738 in Patients With Adv
 anced Solid Tumours and Lymphoma\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03829254
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970497-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05970497)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study Asses
 sing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumor
 s\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05970497
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524935-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05524935)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Olaparib in Combina
 tion With Pembrolizumab for Advanced Uveal Melanoma\nEstimated primary com
 pletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05524935
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05111574-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05111574)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Using Nivolumab Alone o
 r With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery\nEsti
 mated primary completion: 15 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05111574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663775-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05663775)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Prophylactic Mesalamine
  to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Niv
 o)\nEstimated primary completion: August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05663775
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663775-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05663775)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Prophylactic Mesalamin
 e to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Ni
 vo)\nEstimated primary completion: August 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05663775
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06414590-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06414590)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp for Uveal Melanoma\nEstimated primary completion:
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebenta
 fusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06414590
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896839-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05896839)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Immunotherapy in Comb
 ination With Prednisone and Sirolimus for Kidney Transplant Recipients Wit
 h Unresectable or Metastatic Skin Cancer\nEstimated primary completion: 2 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 896839
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896839-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05896839)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Immunotherapy in Com
 bination With Prednisone and Sirolimus for Kidney Transplant Recipients Wi
 th Unresectable or Metastatic Skin Cancer\nEstimated primary completion: 2
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05896839
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\,
  Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary co
 mpletion: September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06594991
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\,
  Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary co
 mpletion: September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06594991
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\, 
 Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06594991
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04309409-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04309409)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Adjuvant Nivolumab Trea
 tment in Stage II (IIA\, IIB\, IIC) High-risk Melanoma\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04309409
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063875-5442@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07063875)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Adding 
 IL-2 to Tebentafusp to Eradicate Cancer Progression\nEstimated primary com
 pletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/aldesleukin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07063875
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112314-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06112314)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: IMC-F106C Regimen Versu
 s Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-
 301)\nEstimated primary completion: 16 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288203-10883@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT07288203)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2\, Melanoma.\nStudy: A Study of L
 ifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07288203
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771544-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06771544)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Metronomic Cyclopho
 sphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06771544
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565285-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07565285)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: The Efficacy and Sa
 fety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Me
 lanoma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07565285
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230613-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07230613)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neo-adjuvant Immunother
 apy in Patients With Localized Melanoma\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 30613
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230613-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07230613)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neo-adjuvant Immunothe
 rapy in Patients With Localized Melanoma\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7230613
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057596-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07057596)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07057596
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Nivolumab With Trametin
 ib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients Wi
 th BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimate
 d primary completion: 8 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Trametinib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Nivolumab With Trameti
 nib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients W
 ith BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimat
 ed primary completion: 8 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Binimetinib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Nivolumab With Tramet
 inib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients 
 With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstima
 ted primary completion: 8 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Encorafenib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Nivolumab With Tramet
 inib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients 
 With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstima
 ted primary completion: 8 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Nivolumab With Trameti
 nib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients W
 ith BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimat
 ed primary completion: 8 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05275374-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05275374)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XP
 -102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Pat
 ients With a BRAF V600 Mutation\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0527537
 4
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01989585-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT01989585)
DESCRIPTION:Trametinib\, phase 1/2\, Melanoma.\nStudy: Testing the Addition
  of Navitoclax to the Combination of Dabrafenib and Trametinib in People W
 ho Have BRAF Mutant Melanoma\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01989585
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01989585-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT01989585)
DESCRIPTION:Dabrafenib\, phase 1/2\, Melanoma.\nStudy: Testing the Addition
  of Navitoclax to the Combination of Dabrafenib and Trametinib in People W
 ho Have BRAF Mutant Melanoma\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01989585
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817901-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07817901)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Melanoma.\nStudy: Phase 1b/2 Clinic
 al Trial to Evaluate the Safety and Efficacy of Combination Therapy With P
 embrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malig
 nant Melanoma\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07817901
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05655312-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05655312)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: MC1R-targeted Alpha-p
 article Monotherapy and Combination Therapy Trial With Nivolumab in Adults
  With Advanced Melanoma\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05655312
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direct
 ed by Genetic Testing in Treating Patients With Advanced Refractory Solid 
 Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1979@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Binimetinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Dire
 cted by Genetic Testing in Treating Patients With Advanced Refractory Soli
 d Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2236@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406724-2521@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HS-IT101: Phase 2 readout est. (NCT07406724)
DESCRIPTION:HS-IT101\, phase 2\, Melanoma.\nStudy: HS-IT101 Injection Versu
 s Chemotherapy in the Treatment of Advanced Melanoma（FASTIL-Mela02）\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hs-it101#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07406724
URL:https://assetmemo.bio/drug/hs-it101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Encorafenib and biNime
 tinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant me
 lanOma and Symptomatic Brain Metastases\nEstimated primary completion: Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 87088
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-1996@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Binimetinib: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Encorafenib and biNim
 etinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant m
 elanOma and Symptomatic Brain Metastases\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/binimetin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6887088
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Encorafenib and biNim
 etinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant m
 elanOma and Symptomatic Brain Metastases\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafen
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6887088
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: Encorafenib and biNimet
 inib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant mel
 anOma and Symptomatic Brain Metastases\nEstimated primary completion: Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06887
 088
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05779423-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05779423)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Cryoablation+Ipilimumab
 +Nivolumab in Melanoma\nEstimated primary completion: 1 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05779423
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05779423-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05779423)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Cryoablation+Ipilimuma
 b+Nivolumab in Melanoma\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05779423
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194929-2219@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Encorafenib: Phase 1/2 readout est. (NCT06194929)
DESCRIPTION:Encorafenib\, phase 1/2\, Melanoma.\nStudy: Defactinib and Avut
 ometinib\, With or Without Encorafenib\, for the Treatment of Patients Wit
 h Brain Metastases From Cutaneous Melanoma\nEstimated primary completion: 
 15 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enco
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06194929
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054555-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06054555)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: A Study to Evaluate ABP
  206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or M
 etastatic Melanoma\nEstimated primary completion: 25 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06054555
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163820-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06163820)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Bevacizumab and ICIs 
 + hSRT in Symptomatic Melanoma Brain Metastases\nEstimated primary complet
 ion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06163820
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163820-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06163820)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Bevacizumab and ICIs
  + hSRT in Symptomatic Melanoma Brain Metastases\nEstimated primary comple
 tion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06163820
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04752826-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04752826)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: BI-1808 as 
 a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanc
 ed Malignancies(Keynote-D20)\nEstimated primary completion: 31 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04752826
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02332668-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02332668)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of Pe
 mbrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tum
 or or Lymphoma (MK-3475-051/KEYNOTE-051)\nEstimated primary completion: 2 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02332668
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627244-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06627244)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Study of Tebentafusp and Radioembolization in the Treatment of Metastatic
  Uveal Melanoma\nEstimated primary completion: 17 February 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06627244
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862530-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280227
DTEND;VALUE=DATE:20280228
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07862530)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant RP2 + Nivol
 umab in Patients With Melanoma\nEstimated primary completion: 27 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07862530
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapie
 s in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvant
  Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary comple
 tion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06999980
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvan
 t Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06999980
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvan
 t Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 latlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06999980
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05549297)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Tebentafusp Regimen
  Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEB
 E-AM)\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT05549297)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Melanoma.\nStudy: Teben
 tafusp Regimen Versus Investigator's Choice in Previously Treated Advanced
  Melanoma (TEBE-AM)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05727904)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Study to Investigat
 e Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone 
 in Participants With Untreated Advanced Melanoma.\nEstimated primary compl
 etion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05727904
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-10883@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Amtagvi (lifileucel): Phase 3 readout est. (NCT05727904)
DESCRIPTION:Amtagvi (lifileucel)\, phase 3\, Melanoma.\nStudy: Study to Inv
 estigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab
  Alone in Participants With Untreated Advanced Melanoma.\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lifileucel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05727904
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor 
 Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatli
 mab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimate
 d primary completion: 17 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor
  Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatl
 imab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimat
 ed primary completion: 17 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor
  Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatl
 imab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimat
 ed primary completion: 17 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05423262-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05423262)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: A Study of TRK-950 in
  Patients With Advanced Solid Tumors\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054232
 62
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, 
 Single Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlim
 ab\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstim
 ated primary completion: 24 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, 
 Single Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlim
 ab\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstim
 ated primary completion: 24 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, S
 ingle Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlima
 b\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstima
 ted primary completion: 24 May 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03767348)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03767348
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-2713@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 2 readout est. (NCT0376
 7348)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 2\, Non-Small Cell
  Lung Cancer.\nStudy: Study of RP1 Monotherapy and RP1 in Combination With
  Nivolumab (IGNYTE)\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqe
 v#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 767348
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02621021-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02621021)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: A Phase 2 Trial for
  Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating L
 ymphocytes Plus IL-2 Either Alone or Following the Administration of Pembr
 olizumab\nEstimated primary completion: 16 June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02621021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03175432-1962@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03175432)
DESCRIPTION:Atezolizumab\, phase 2\, Melanoma.\nStudy: Bevacizumab and Atez
 olizumab With or Without Cobimetinib in Treating Patients With Untreated M
 elanoma Brain Metastases\nEstimated primary completion: 30 June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03175432
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03175432-2167@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT03175432)
DESCRIPTION:Cobimetinib\, phase 2\, Melanoma.\nStudy: Bevacizumab and Atezo
 lizumab With or Without Cobimetinib in Treating Patients With Untreated Me
 lanoma Brain Metastases\nEstimated primary completion: 30 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03175432
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615881-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07615881)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Comparing Intravenou
 s or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD
 1 Treatment in Patients With Melanoma\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07615881
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284590-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06284590)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Study of the Effica
 cy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF\, in Combination With
  Pembrolizumab\, in Unresectable Melanoma Patients\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06284590
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961006-2042@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06961006)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People Wi
 th Melanoma (V940-012/INTerpath-012)\nEstimated primary completion: 22 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/intismeran-au
 togene#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06961006
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909618-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05909618)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Crizanlizumab Alone or 
 in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Met
 astases\nEstimated primary completion: 30 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05909618
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631325-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07631325)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Axelopran and Nivolum
 ab in PD-1-Refractory Metastatic Melanoma\nEstimated primary completion: 3
 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 631325
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704647-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05704647)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Phase II Study of Nivol
 umab in Combination With Relatlimab in Patients With Active Melanoma Brain
  Metastases\nEstimated primary completion: 31 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05704647
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704647-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05704647)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Phase II Study of Nivo
 lumab in Combination With Relatlimab in Patients With Active Melanoma Brai
 n Metastases\nEstimated primary completion: 31 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05704647
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06070012-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06070012)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal 
 Melanoma\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06070012
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuvan
 t Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimated
  primary completion: November 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuva
 nt Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuva
 nt Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883759-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07883759)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Pembrol
 izumab in Patients With High Risk\, Stage IIB/IIC Cutaneous Melanoma: a Si
 ngle Arm Proof of Concept Phase IIA Study.\nEstimated primary completion: 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07883759
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624644-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06624644)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Melanoma.\nStudy: A Trial of LNS880
 1 With or Without Pembrolizumab in Patients With Refractory Melanoma\nEsti
 mated primary completion: February 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06624644
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624644-2596@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:LNS8801: Phase 2/3 readout est. (NCT06624644)
DESCRIPTION:LNS8801\, phase 2/3\, Melanoma.\nStudy: A Trial of LNS8801 With
  or Without Pembrolizumab in Patients With Refractory Melanoma\nEstimated 
 primary completion: February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lns8801#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06624644
URL:https://assetmemo.bio/drug/lns8801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527325-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07527325)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Fianlimab&Cemiplimab a
 s TotalNeoadj The (TNT) ForMelanoma\nEstimated primary completion: 1 Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0752
 7325
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527325-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07527325)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: Fianlimab&Cemiplimab as
  TotalNeoadj The (TNT) ForMelanoma\nEstimated primary completion: 1 Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075273
 25
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare
 -Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary comple
 tion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07740941
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare-Adj
 uvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary completion
 : March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7740941
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare-Ad
 juvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary completio
 n: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilim
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07740941
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01590069-5442@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT01590069)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Aerosol
 ized Aldesleukin in Treating Patients With Lung Metastases\nEstimated prim
 ary completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/aldesleukin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT01590069
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition o
 f Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pri
 mary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07504796
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition 
 of Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07504796
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Relatlimab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition 
 of Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07504796
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349303-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07349303)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Pembrol
 izumab in Patients With Stage IIb/c Melanoma\nEstimated primary completion
 : 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07349303
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06060613-2650@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:OBX-115: Phase 1/2 readout est. (NCT06060613)
DESCRIPTION:OBX-115\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of OBX-115 in Advanced Solid Tumors\nEstimated primary comp
 letion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obx-115#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06060613
URL:https://assetmemo.bio/drug/obx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06240143-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06240143)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Intradermal Ipilimuma
 b and Nivolumab in High Risk Stage II Melanoma\nEstimated primary completi
 on: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06240143
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06240143-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06240143)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Intradermal Ipilimum
 ab and Nivolumab in High Risk Stage II Melanoma\nEstimated primary complet
 ion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipili
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06240143
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449754-2167@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT07449754)
DESCRIPTION:Cobimetinib\, phase 2\, Melanoma.\nStudy: Belvarafenib in Combi
 nation With Cobimetinib in Patients With Locally Advanced or Metastatic NR
 AS-Mutant Melanoma\nEstimated primary completion: September 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07449754
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770102-1962@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05770102)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: DETERMINE
  Trial Treatment Arm 02: Atezolizumab in Adult\, Paediatric and Teenage/Yo
 ung Adult Patients With Cancers With High Tumour Mutational Burden (TMB) o
 r Microsatellite Instability-high (MSI-high) or Proven Constitutional Mism
 atch Repair Deficiency (CMMRD) Disposition\nEstimated primary completion: 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05770102
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768178-2167@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT05768178)
DESCRIPTION:Cobimetinib\, phase 2/3\, Melanoma.\nStudy: DETERMINE Trial Tre
 atment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patien
 ts With BRAF Positive Cancers.\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05768178
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768178-2273@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Vemurafenib: Phase 2/3 readout est. (NCT05768178)
DESCRIPTION:Vemurafenib\, phase 2/3\, Melanoma.\nStudy: DETERMINE Trial Tre
 atment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patien
 ts With BRAF Positive Cancers.\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05768178
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933577-2042@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT05933577)
DESCRIPTION:Intismeran Autogene\, phase 3\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-R
 isk Melanoma (V940-001)\nEstimated primary completion: 26 October 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0593357
 7
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976021-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976021)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Immune PET a
 nd Proteomics for the Assessment of Response to Spatially Fractionated or 
 Palliative Radiotherapy With or Without Immunotherapy\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06976021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Nivolumab\, phase 2/3\, Melanoma.\nStudy: A Randomized\, Phase 
 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination Wit
 h Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Meta
 static Uveal Melanoma\nEstimated primary completion: January 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06581406
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Ipilimumab\, phase 2/3\, Melanoma.\nStudy: A Randomized\, Phase
  2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination Wi
 th Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Met
 astatic Uveal Melanoma\nEstimated primary completion: January 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06581406
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718243-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07718243)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Inv
 estigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours\
 , Melanoma and NSCLC\nEstimated primary completion: 31 January 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07718243
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413680-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06413680)
DESCRIPTION:Cemiplimab\, phase 1/2\, Melanoma.\nStudy: A First-In Human (FI
 H) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combina
 tion With Cemiplimab Works in Adult Participants Who Have Cancer With Tumo
 rs That Have Spread in Their Body\nEstimated primary completion: 3 Februar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064136
 80
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Find
 ing Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fir
 st Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary comple
 tion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06683755
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Fin
 ding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fi
 rst Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary compl
 etion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06683755
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Relatlimab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Fin
 ding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fi
 rst Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary compl
 etion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06683755
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488482-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06488482)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Assessment of Short
  Immunotherapy After Radical Surgery of High-risk Malignant Melanoma\nEsti
 mated primary completion: September 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06488482
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488482-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06488482)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Assessment of Short Imm
 unotherapy After Radical Surgery of High-risk Malignant Melanoma\nEstimate
 d primary completion: September 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06488482
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06264180-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06264180)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: VO and Nivolumab vs Phy
 sician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-C
 TLA-4 Drugs [IGNYTE-3]\nEstimated primary completion: 30 September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06264180
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06626516-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 1/2 readout est. (NCT06626516)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 1/2\, Uveal Melanoma.\nStud
 y: Tebentafusp-tebn With LDT in Metastatic UM\nEstimated primary completio
 n: October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebe
 ntafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06626516
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848088-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301009
DTEND;VALUE=DATE:20301010
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06848088)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: A Study to Learn About
  the Long-Term Health of Adult Participants From a Previous Study of a New
  Melanoma Treatment\nEstimated primary completion: 9 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06848088
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848088-2221@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301009
DTEND;VALUE=DATE:20301010
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06848088)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: A Study to Learn About 
 the Long-Term Health of Adult Participants From a Previous Study of a New 
 Melanoma Treatment\nEstimated primary completion: 9 October 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06848088
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930182-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07930182)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Adjuvant/Neoadjuvant Im
 munotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring\nEstimated
  primary completion: 21 October 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07930182
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930182-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07930182)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Adjuvant/Neoadjuvant I
 mmunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring\nEstimate
 d primary completion: 21 October 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07930182
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121180-1975@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06121180)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Study of Cemiplimab Pl
 us Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma\nEstimated 
 primary completion: 31 October 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06121180
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Patie
 nt Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimated p
 rimary completion: 30 November 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281924-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07281924)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Hepzato Kit and Opdua
 lag for Metastatic Melanoma and Liver Metastasis\nEstimated primary comple
 tion: December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07281924
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281924-2059@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT07281924)
DESCRIPTION:Relatlimab\, phase 1/2\, Melanoma.\nStudy: Hepzato Kit and Opdu
 alag for Metastatic Melanoma and Liver Metastasis\nEstimated primary compl
 etion: December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07281924
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276386-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07276386)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Me
 tastatic Uveal Melanoma\nEstimated primary completion: December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07276386
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05155033)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase I
 I Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma a
 nd Renal Cell Carcinoma\nEstimated primary completion: 1 September 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05155033
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-5442@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT05155033)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2\, Renal Cell Carcinoma.\nStud
 y: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic 
 Melanoma and Renal Cell Carcinoma\nEstimated primary completion: 1 Septemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0515
 5033
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794775-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20320415
DTEND;VALUE=DATE:20320416
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06794775)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: SWE-NEO: Swedish NeoAdj
 uvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable 
 Stage III Melanoma\nEstimated primary completion: 15 April 2032. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06794775
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794775-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20320415
DTEND;VALUE=DATE:20320416
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT06794775)
DESCRIPTION:Ipilimumab\, phase 3\, Melanoma.\nStudy: SWE-NEO: Swedish NeoAd
 juvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable
  Stage III Melanoma\nEstimated primary completion: 15 April 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06794775
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimated p
 rimary completion: 30 April 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940739-10883@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Amtagvi (lifileucel): Phase 1/2 readout est. (NCT06940739)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1/2\, Melanoma.\nStudy: A Study to
  Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced M
 elanoma Who Will Receive Lifileucel\nEstimated primary completion: June 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lifileucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06940739
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246149-10942@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT06246149)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Uveal Melanoma.\nStudy:
  Adjuvant Tebentafusp in High Risk Ocular Melanoma\nEstimated primary comp
 letion: November 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tebentafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06246149
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897881-2042@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20321121
DTEND;VALUE=DATE:20321122
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT03897881)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: An Efficacy S
 tudy of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 
 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)\nE
 stimated primary completion: 21 November 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03897881
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02339571-1974@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT02339571)
DESCRIPTION:Nivolumab\, phase 2/3\, Melanoma.\nStudy: A Phase II/III Trial 
 of Nivolumab\, Ipilimumab\, and GM-CSF in Patients With Advanced Melanoma\
 nEstimated primary completion: 30 June 2033. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT02339571
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02339571-2009@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT02339571)
DESCRIPTION:Ipilimumab\, phase 2/3\, Melanoma.\nStudy: A Phase II/III Trial
  of Nivolumab\, Ipilimumab\, and GM-CSF in Patients With Advanced Melanoma
 \nEstimated primary completion: 30 June 2033. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT02339571
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697301-2115@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Resiquimod: Phase 2/3 readout est. (NCT06697301)
DESCRIPTION:Resiquimod\, phase 2/3\, Melanoma.\nStudy: Safety and Efficacy 
 of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Th
 erapy in Patients With Advanced Melanoma.\nEstimated primary completion: D
 ecember 2035. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/resiqui
 mod#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06697301
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
